Assembly Announces Breakthrough in Optimising TCR Assets
Etcembly Announces Breakthrough in Optimising TCR Assets. Successful Financing Brings in Singapore VC iGlobe Partners.
top of page
![E3353_06 [ALT4ax].png](https://static.wixstatic.com/media/73af19_3c2aa92876234a68b46bead64acb0ce5~mv2.png/v1/fill/w_957,h_947,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/73af19_3c2aa92876234a68b46bead64acb0ce5~mv2.png)
- Mar 15, 2022
Etcembly Appoints Scott Cuthill as Chief Business Officer
Etcembly Appoints Scott Cuthill as Chief Business Officer. The Oxford based company is transforming TCR immunotherapy research.
357 views
- Feb 7, 2022
Research Complex at Harwell welcomes Etcembly
Research Complex at Harwell is delighted to welcome Etcembly. The company is continuing to expand to realise its goal to assemble the...
140 views
- Feb 7, 2022
Etcembly establishes new lab & office space at Oxford Science Park
Immune-focused machine learning firm joins leading AI cohort on Park Etcembly Ltd has moved into more than 1,000 square feet of new...
156 views
- Feb 7, 2022
Zelluna Immunotherapy AS Announces Exclusive Research Collaboration with Etcembly Limited
Oslo, Norway and Oxford, UK: 29th April 2021. Zelluna Immunotherapy AS announces an exclusive research collaboration with Etcembly Ltd to...
173 views
- Feb 7, 2022
Oxford-based machine learning start-up Etcembly secures Private Seed Funding
Oxford, UK: 23rd April 2021. No embargo. Etcembly Ltd (Etcembly), a company building a platform to decode immune repertoires in health...
281 views
bottom of page